Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call

Full Transcript: Regenxbio Q2 2026 Earnings Call

Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22

(RGNX) Price Dynamics and Execution-Aware Positioning

Regenxbio Stock Price Forecast. Should You Buy RGNX?

uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish

Regenxbio stock gains on positive gene therapy trial data

Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids

REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

$RGNX stock is down 10% today. Here's what we see in our data.

REGENXBIO to Participate in Upcoming Investor Conferences